BioNTech’s Triple Pivot: Founders Step Back, Factories Go on the Block, and Oncology Data Looms
Ugur Sahin and Özlem Türeci built BioNTech from a Mainz lab into a global vaccine powerhouse. By the end of ...
Tag: BioNTech
BioNTech Faces a Summer of Reckoning as Vaccine Revenues Wane and Oncology Data Takes Center Stage
BioNTech enters a critical stretch with no single event to anchor investor sentiment. The German biotech’s stock closed at €80.20 ...
BioNTech’s Oncology Ambition Faces a Trio of Tests: Clinical Data, Founder Departure, and Deep Cost-Cutting
BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at ...
BioNTech Rolls Out a $1 Billion Buyback While Racing Toward Its First Cancer Approval
BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as ...
BioNTech Fields a $1 Billion Buyback and a Moderna Plant Bid While Eyeing a Cancer-Fueled Future
The German biotech group BioNTech is sending two very different signals to the market at once. Its management is busy ...
BioNTech Bets Big on Oncology as $1 Billion Buyback and First FDA Filing Converge
The Mainz-based biotech firm finds itself in an unusual position: burning through cash on R&D while sitting on a €16.8 ...
BioNTech at a Crossroads: FDA Filing Looms as Phase 3 Pipeline Takes Shape
The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving ...
BioNTech’s Oncology Data Wows, but the Stock Won’t Budge: A $1 Billion Buyback Meets Investor Skepticism
The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for ...
BioNTech’s Bet on BNT323 Intensifies as Restructuring and Pipeline Data Pave Way for Regulatory Milestone
The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a ...
BioNTech’s $650 Million R&D Quarter: Shareholders Back Board Expansion as Market Awaits Lung Cancer Data
Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races ...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
